Psychotropic drugs and the elderly fast facts : fast facts / Joel Sadavoy.
By: Sadavoy, Joel.
Material type:
BookSeries: Fast facts (New York, N.Y.): Publisher: New York : W.W. Norton, c2004Edition: 1st ed.Description: xix, 749 p. ; 22 cm.Content type: text Media type: unmediated Carrier type: volumeISBN: 0393703754; 9780393703757.Other title: Psychotropic drugs and the elderly [Cover title].Subject(s): Psychotropic drugs
| Pharmacokinetics | Geriatric psychopharmacology | Psychotropic Drugs -- pharmacology -- Aged | Psychotropic Drugs -- therapeutic use -- Aged | Geriatric medicine | Psychopharmacology | Psychiatry | PharmacologyDDC classification: 615.788 SAD Summary: Psychotropic drugs are used widely with the elderly, but formal knowledge and training are often poor. With a focus on geriatric considerations such as medical issues, disabilities and nursing-home situations, this handbook gives clinicians the facts they need to work with elderly clients.
| Item type | Current library | Call number | Copy number | Status | Barcode | |
|---|---|---|---|---|---|---|
| General lending | MTU Kerry North Campus Library First Floor Main | 615.788 SAD (Browse shelf(Opens below)) | 1 | Available | 38888000538029 |
Enhanced descriptions from Syndetics:
Medical issues typically presented by seniors, disabilities that accompany the aging process, and nursing home situations are addressed throughout so as to give clinicians the facts they need to work with elderly clients. All major drug classes receive comprehensive coverage: antidepressants, antipsychotics, anxiolytics, mood stabilizers, and cognitive enhancers. For each class, Sadavoy addresses the impact that changes in human physiology have on the standard directives for prescription and the necessary warnings regarding side effects and cross-indication. A wide range of disorders is addressed with particular emphasis on disturbances and disorders that are encountered when treating the mental health of the elderly: Alzheimer's Disease and other forms of dementia, behavioral disturbances, anxiety and depression, mania and other mood disorders, and various forms and presentations of psychosis. The comprehensive presentation of dispensing directions is rigorously based on the most current research and accepted clinical practice. Psychotropic Drugs and the Elderly: Fast Facts is organized in the same format as Norton's other titles in the highly successful "Fast Facts" series with individual chapters devoted to classes of medications and all critical information presented in easy-to-read tables and charts. With authoritative content and a well-planned presentation, this handy guide is essential reading for physicians, psychogeriatricians and all mental health professionals who treat the elderly.
"A Norton professional book."
Includes bibliographical references (p. 641-725) and index.
Psychotropic drugs are used widely with the elderly, but formal knowledge and training are often poor. With a focus on geriatric considerations such as medical issues, disabilities and nursing-home situations, this handbook gives clinicians the facts they need to work with elderly clients.
Table of contents provided by Syndetics
- Abbreviations (p. xiii)
- Acknowledgments (p. xix)
- Introduction (p. 3)
- Structure and Goals of the Book (p. 4)
- Research and Sources of Data (p. 6)
- Challenges Posed by the Data (p. 7)
- Dosing Challenges (p. 8)
- Side-Effect Challenges (p. 9)
- The Importance of Basic Pharmacology (p. 10)
- Indications and Contraindications (p. 10)
- Overview of General Pharmacokinetics and Pharmacodynamics (p. 11)
- 1. Antidepressants (p. 23)
- Overview (p. 23)
- Depressive Disorders in Elders (p. 24)
- Non-Depressive Disorders for which Antidepressants Are Used (p. 38)
- Geriatric Antidepressant Pharmacotherapy Issues (p. 45)
- Choosing and Using Specific Antidepressants (p. 49)
- Phases of Antidepressant Treatment (p. 53)
- Prognosis of Depression with Treatment (p. 55)
- Nonresponse to Antidepressant Treatment (p. 58)
- Depression Therapy Decision Pathways (p. 65)
- Side Effects of Antidepressants (p. 70)
- Receptor Affinity-Side-Effect Relationship (p. 89)
- Drug-Drug Interactions (p. 90)
- Family and Caregivers (p. 96)
- Heterocyclic Antidepressants (p. 97)
- Irreversible MAOIs (p. 111)
- Selective Serotonin Reuptake Inhibitors (SSRIs) (p. 123)
- Individual Antidepressant Drug Profiles (p. 135)
- Buproprion (BUP) (p. 135)
- Citalopram (p. 144)
- Clomipramine (p. 151)
- Desipramine (p. 155)
- Duloxetine (p. 157)
- Escitalopram (p. 158)
- Fluoxetine (p. 158)
- Mirtazapine (p. 166)
- Moclobemide (p. 174)
- Nefazodone (p. 179)
- Nortriptyline (p. 186)
- Paroxetine (p. 191)
- Phenelzine (p. 200)
- Sertraline (p. 202)
- St. John's Wort (p. 209)
- Trazodone (p. 210)
- Venlafaxine (p. 217)
- 2. Antipsychotic Agents (p. 229)
- Overview (p. 229)
- Atypical Antipsychotics (p. 231)
- Typical Antipsychotics (p. 232)
- Clinical Conditions Treated with Antipsychotic Agents (p. 236)
- Principles of Treatment with Antipsychotics (p. 262)
- Neuropharmacology of Neuroleptics (p. 266)
- Choosing an Antipsychotic Drug (p. 266)
- Administration and Dosing (p. 273)
- Side Effects of Antipsychotics (p. 279)
- Side Effects of Antipsychotic Drug Class (p. 281)
- Antiparkinsonian Agents (p. 303)
- Drug-Drug Interactions (p. 306)
- Overdose with Typical Antipsychotics (p. 307)
- Overdose with Atypical Antipsychotics (p. 308)
- Individual Antipsychotic Drug Profiles (p. 308)
- Aripiprazole (p. 308)
- Clozapine (p. 308)
- Fluphenazine (p. 322)
- Haloperidol (p. 325)
- Loxapine (p. 332)
- Olanzapine (p. 334)
- Perphenazine (p. 342)
- Quetiapine (p. 345)
- Risperidone (p. 350)
- Thioridazine (p. 359)
- Thiothixene (p. 363)
- Ziprasidone (p. 366)
- 3. Antianxiety Drugs and Sedative/Hypnotics (p. 371)
- Overview (p. 371)
- Benzodiazepines (p. 372)
- Pharmacology (p. 376)
- Geriatric Issues (p. 386)
- Anxiety Disorders (p. 394)
- Other Conditions Where Benzodiazepines May be Used (p. 400)
- Side Effects (p. 401)
- Drug-Drug Interactions (p. 410)
- Sleep Disorders (p. 411)
- Alcohol Abuse and Alcoholism (p. 423)
- Discontinuation/Withdrawal and Rebound Syndromes (p. 426)
- Overdose (p. 429)
- Individual Anti-Anxiety and Sedative/Hypnotic Drug Profiles (p. 430)
- Alprazolam (p. 430)
- Buspirone (p. 436)
- Chloral Hydrate (p. 441)
- Clonazepam (p. 444)
- Diazepam (p. 446)
- Estazolam (p. 448)
- Lorazepam (p. 449)
- Midazolam (p. 453)
- Oxazepam (p. 455)
- Temazepam (p. 457)
- Triazolam (p. 459)
- Zaleplon (p. 462)
- Zolpidem (p. 465)
- Zopiclone (p. 471)
- Herbal Remedies (p. 474)
- 4. Mood Stabilizers (p. 479)
- Overview (p. 479)
- Pharmacology (p. 482)
- Indications for Mood Stabilizers (p. 485)
- Bipolar Disorder (p. 485)
- Treatment of Bipolar Disorder (p. 492)
- Individual Mood Stabilizer Drug Profiles (p. 502)
- Carbamazepine (p. 502)
- Gabapentin (p. 509)
- Lamotrigine (p. 513)
- Lithium (p. 516)
- Topiramate (p. 538)
- Valproic Acid, Valproate, Divalproex (p. 541)
- 5. Cognitive Enhancers (p. 551)
- Overview (p. 551)
- Pharmacology (p. 553)
- Clinical Indications: Dementia (p. 554)
- Treatment of Dementia (p. 564)
- Cautions and Contraindications (p. 571)
- Donepezil (p. 574)
- Galantamine (p. 582)
- Rivastigmine (p. 587)
- Tacrine (p. 592)
- Appendix A Newly Approved Drugs (p. 597)
- Aripiprazole (p. 597)
- Escitalopram (p. 599)
- Appendix B Profile of Psychotropic Drugs (p. 605)
- Antidepressants (p. 605)
- Antipsychotics (p. 617)
- Anxiolytics/Hypnotics (p. 628)
- Mood Stabilizers (p. 634)
- Cognitive Enhancers (p. 638)
- References (p. 641)
- Index (p. 727)